This investigation has raised concerns about potential legal and reputational ... the approval process for Pfizer’s vaccine candidates. Despite these challenges, Pfizer maintains a Moderate ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE ... rebounded after Wall Street analysts highlighted the significant legal challenges the order would face. The pharmaceutical industry has ...

In a landmark decision that challenges the European Commission’s transparency standards, the General Court of the European ...

Global pharmaceutical shares jumped in intraday trading Monday, reversing their pre-market declines, as investors anticipated ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... These frameworks provide patients and developers with legal protection by simplifying liability standards for flawed ...

According to InvestingPro data, the company faces significant financial challenges ... ITIL agreed to cover a transaction fee and Pfizer’s legal expenses. Iterum’s CEO, Corey Fishman ...

Pfizer Inc (NYSE:PFE) experienced a 6% operational revenue decline in Q1 2025, largely due to lower Paxlovid revenues and changes in Medicare Part D design. The company faces challenges from ...

The pressure to strategize on its pipeline comes as Pfizer prepares for new challenges. The company is bracing for a more than $15 billion loss over the next decade as patents for six major drugs ...

Ratings for Pfizer PFE were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings ...